EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcome of treatment of autoimmune uveitis by conventional immunomodulatory drugs versus biologic drugs in a tertiary hospital in Upper Egypt

Elham Y. Ahmed, Hassan L. Fahmi, Eman A. Elkady, Mohamed G.A. Saleh

Delta Journal of Ophthalmology · 2026-10 · 27 (4) · 294-300

DOI: 10.4103/djo.djo_19_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Delta Journal of Ophthalmology, online erschienen am 19.11.2026. Verfasst von Elham Y. Ahmed und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to assess the efficacy and safety of conventional immunomodulatory drugs compared to biologic response-modifying agents in autoimmune uveitis (AIU) treatment in a tertiary hospital in Upper Egypt. Patients and methods This is a retrospective review of the records of 74 AIU patients who were managed at the Uveitis Unit in collaboration with the Department of Rheumatology, Rehabilitation, and Physical Medicine, Faculty of Medicine, Assiut University Hospital, Assiut, Egypt from January 2017 to May 2023. Each case was evaluated through a detailed history, full ophthalmological and rheumatological examinations, and relevant laboratory and imaging studies. Infectious causes were excluded and drug safety was monitored throughout.

Results

Of the 74 patients, 40 received conventional immunomodulatory drugs (group 1), while 34 were treated with biologics (group 2). The mean age of the patients in group 1 was 34.20±8.78 years compared to 33.29±8.02 years in group 2 ( P =0.647). The most frequent causes of AIU were Behçet’s disease (55.4%), Vogt–Koyanagi–Harada disease (13.5%), and seronegative spondyloarthropathies (12.2%). The disease control was significantly better in the biologics group (79.4% of the cases were adequately controlled) than in the conventional treatment group (55%) ( P =0.049). Regarding the side effects, nine (22.5%) cases of the conventional treatment group developed side effects versus five (14.7%) cases in the biologics group, with a statistically significant difference ( P =0.018). The most common adverse effects in the conventional group were bone marrow suppression and gastrointestinal toxicity. In contrast, severe pneumonia was the most serious complication in the biologics group. Furthermore, significantly fewer patients (47.1%) in the biologics group required additional doses of systemic corticosteroids compared to 72.5% in the conventional treatment group ( P =0.025).

Conclusions

The biologic therapies showed greater efficacy in controlling the AIU and enabled steroid-sparing effects, particularly in the sight-threatening cases. Conventional immunomodulatory drugs may still be considered as first-line treatment in the cases where biologics are contraindicated or less accessible.

Zitieren

APA

Ahmed, E. Y., Fahmi, H. L., Elkady, E. A., & Saleh, M. G. (2026). Outcome of treatment of autoimmune uveitis by conventional immunomodulatory drugs versus biologic drugs in a tertiary hospital in Upper Egypt. Delta Journal of Ophthalmology, 27(4), 294-300. https://doi.org/10.4103/djo.djo_19_26

Vancouver

Ahmed EY, Fahmi HL, Elkady EA, Saleh MG. Outcome of treatment of autoimmune uveitis by conventional immunomodulatory drugs versus biologic drugs in a tertiary hospital in Upper Egypt. Delta Journal of Ophthalmology. 2026;27(4):294-300. doi:10.4103/djo.djo_19_26

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Elham Y. and Fahmi, Hassan L. and Elkady, Eman A. and Saleh, Mohamed G.A.},
  title = {Outcome of treatment of autoimmune uveitis by conventional immunomodulatory drugs versus biologic drugs in a tertiary hospital in Upper Egypt},
  journal = {Delta Journal of Ophthalmology},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {294--300},
  doi = {10.4103/djo.djo_19_26}
}
Kostenlos starten →